168 related articles for article (PubMed ID: 34565765)
1. Circulating PCSK7 Level is Independently Associated with Obesity, Triglycerides Level and Fatty Liver Index in a General Population without Medication.
Furuhashi M; Kataoka Y; Nishikawa R; Koyama M; Sakai A; Higashiura Y; Tanaka M; Saitoh S; Shimamoto K; Ohnishi H
J Atheroscler Thromb; 2022 Sep; 29(9):1275-1284. PubMed ID: 34565765
[TBL] [Abstract][Full Text] [Related]
2. Independent Link Between Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and FABP4 in a General Population Without Medication.
Furuhashi M; Omori A; Matsumoto M; Kataoka Y; Tanaka M; Moniwa N; Ohnishi H; Yoshida H; Saitoh S; Shimamoto K; Miura T
Am J Cardiol; 2016 Jul; 118(2):198-203. PubMed ID: 27241838
[TBL] [Abstract][Full Text] [Related]
3.
Dongiovanni P; Meroni M; Baselli G; Mancina RM; Ruscica M; Longo M; Rametta R; Cespiati A; Pelusi S; Ferri N; Ranzani V; Nobili V; Pihlajamaki J; Fracanzani AL; Badiali S; Petta S; Fargion S; Romeo S; Kozlitina J; Valenti L
J Lipid Res; 2019 Jun; 60(6):1144-1153. PubMed ID: 30918065
[TBL] [Abstract][Full Text] [Related]
4. PCSK7: A novel regulator of apolipoprotein B and a potential target against non-alcoholic fatty liver disease.
Sachan V; Le Dévéhat M; Roubtsova A; Essalmani R; Laurendeau JF; Garçon D; Susan-Resiga D; Duval S; Mikaeeli S; Hamelin J; Evagelidis A; Chong M; Paré G; Chernetsova E; Gao ZH; Robillard I; Ruiz M; Trinh VQ; Estall JL; Faraj M; Austin RC; Sauvageau M; Prat A; Kiss RS; Seidah NG
Metabolism; 2024 Jan; 150():155736. PubMed ID: 37967646
[TBL] [Abstract][Full Text] [Related]
5. The rs508487, rs236911, and rs236918 Genetic Variants of the Proprotein Convertase Subtilisin-Kexin Type 7 (
Vargas-Alarcón G; Pérez-Méndez O; González-Pacheco H; Ramírez-Bello J; Posadas-Sánchez R; Escobedo G; Fragoso JM
Cells; 2021 Jun; 10(6):. PubMed ID: 34207761
[TBL] [Abstract][Full Text] [Related]
6. Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.
Hamamura H; Adachi H; Enomoto M; Fukami A; Nakamura S; Nohara Y; Morikawa N; Sakaue A; Toyomasu K; Yamamoto M; Fukumoto Y
J Atheroscler Thromb; 2021 Apr; 28(4):329-337. PubMed ID: 32624555
[TBL] [Abstract][Full Text] [Related]
7. Variations in TM6SF2, PCSK9 and PCSK7 genes and risk of hepatic steatosis after liver transplantation: a cross-sectional study.
Eshraghian A; Moasser E; Azarpira N; Fattahi MR; Nikeghbalian S; Malek-Hosseini SA; Geramizadeh B
BMC Gastroenterol; 2021 Dec; 21(1):458. PubMed ID: 34876018
[TBL] [Abstract][Full Text] [Related]
8. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease.
Motamed N; Sohrabi M; Ajdarkosh H; Hemmasi G; Maadi M; Sayeedian FS; Pirzad R; Abedi K; Aghapour S; Fallahnezhad M; Zamani F
World J Gastroenterol; 2016 Mar; 22(10):3023-30. PubMed ID: 26973398
[TBL] [Abstract][Full Text] [Related]
9. Independent Association of Fatty Liver Index With Left Ventricular Diastolic Dysfunction in Subjects Without Medication.
Furuhashi M; Muranaka A; Yuda S; Tanaka M; Koyama M; Kawamukai-Nishida M; Takahashi S; Higashiura Y; Miyamori D; Nishikawa R; Ohnishi H; Saitoh S; Shimamoto K; Miura T
Am J Cardiol; 2021 Nov; 158():139-146. PubMed ID: 34474907
[TBL] [Abstract][Full Text] [Related]
10. Proprotein convertase subtilisin/kexin type 7 (PCSK7) is essential for the zebrafish development and bioavailability of transforming growth factor β1a (TGFβ1a).
Turpeinen H; Oksanen A; Kivinen V; Kukkurainen S; Uusimäki A; Rämet M; Parikka M; Hytönen VP; Nykter M; Pesu M
J Biol Chem; 2013 Dec; 288(51):36610-23. PubMed ID: 24178295
[TBL] [Abstract][Full Text] [Related]
11. Proprotein convertase 7 (PCSK7) reduces apoA-V levels.
Ashraf Y; Duval S; Sachan V; Essalmani R; Susan-Resiga D; Roubtsova A; Hamelin J; Gerhardy S; Kirchhofer D; Tagliabracci VS; Prat A; Kiss RS; Seidah NG
FEBS J; 2020 Aug; 287(16):3565-3578. PubMed ID: 31945259
[TBL] [Abstract][Full Text] [Related]
12. Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.
Li S; Xu RX; Zhang Y; Guo YL; Zhu CG; Liu G; Dong Q; Li JJ
J Endocrinol Invest; 2015 Dec; 38(12):1291-9. PubMed ID: 26003826
[TBL] [Abstract][Full Text] [Related]
13. Association of Hepatic Steatosis Index and Fatty Liver Index with Carotid Atherosclerosis in Type 2 Diabetes.
Wang C; Cai Z; Deng X; Li H; Zhao Z; Guo C; Zhang P; Li L; Gu T; Yang L; Zhao L; Wang D; Yuan G
Int J Med Sci; 2021; 18(14):3280-3289. PubMed ID: 34400897
[No Abstract] [Full Text] [Related]
14. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
Brouwers MC; Troutt JS; van Greevenbroek MM; Ferreira I; Feskens EJ; van der Kallen CJ; Schaper NC; Schalkwijk CG; Konrad RJ; Stehouwer CD
Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
[TBL] [Abstract][Full Text] [Related]
15. Plasma Tsukushi Concentration Is Associated with High Levels of Insulin and FGF21 and Low Level of Total Cholesterol in a General Population without Medication.
Furuhashi M; Higashiura Y; Sakai A; Koyama M; Tanaka M; Saitoh S; Shimamoto K; Ohnishi H
Metabolites; 2022 Mar; 12(3):. PubMed ID: 35323680
[TBL] [Abstract][Full Text] [Related]
16. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
[TBL] [Abstract][Full Text] [Related]
17. Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study.
Shi J; Zhang W; Niu Y; Lin N; Li X; Zhang H; Hu R; Ning G; Fan J; Qin L; Su Q; Yang Z
Cardiovasc Diabetol; 2020 Dec; 19(1):209. PubMed ID: 33302966
[TBL] [Abstract][Full Text] [Related]
18. Fatty liver index (FLI) and prediction of new cases of non-alcoholic fatty liver disease: A population-based study of northern Iran.
Motamed N; Faraji AH; Khonsari MR; Maadi M; Tameshkel FS; Keyvani H; Ajdarkosh H; Karbalaie Niya MH; Rezaie N; Zamani F
Clin Nutr; 2020 Feb; 39(2):468-474. PubMed ID: 30922791
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease, circulating ketone bodies and all-cause mortality in a general population-based cohort.
Post A; Garcia E; van den Berg EH; Flores-Guerrero JL; Gruppen EG; Groothof D; Westenbrink BD; Connelly MA; Bakker SJL; Dullaart RPF
Eur J Clin Invest; 2021 Dec; 51(12):e13627. PubMed ID: 34120339
[TBL] [Abstract][Full Text] [Related]
20. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.
Zelber-Sagi S; Webb M; Assy N; Blendis L; Yeshua H; Leshno M; Ratziu V; Halpern Z; Oren R; Santo E
World J Gastroenterol; 2013 Jan; 19(1):57-64. PubMed ID: 23326163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
